Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers

Abstract

This summary provides an overview of how new therapies or new aspects of established therapies relate to the latest findings. Neoadjuvant therapy, local therapy, new aspects of systemic therapy, and prognostic and predictive factors are presented. In the neoadjuvant setting, the association between pathological complete response (pCR) and prognosis is still of interest as is the identification of new molecular predictors for new therapies such as CDK4/6 inhibitors. As regards surgical treatment, the target is still to reduce the aggressiveness of surgery. To achieve this, a better understanding particularly of ductal carcinoma in situ is required. With regard to systemic therapy, more data on the best combinations and therapy sequences for existing therapies is available. Finally, the use of prognostic and predictive factors may help to avoid overtreatment and ensure that patients only receive therapies which have been shown to be effective for their specific condition and have fewer side effects.

Update Breast Cancer 2018 (Part 3) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer

“…This applies in particular to cancers. The other principles of this Hippocratic tradition such as “second, be careful” and “third, cure” also have their correlates in the current study results, guidelines and treatment recommendations 1 , 2 , 3 . For cancers, this means that the identification of patients with a good and poor prognosis, with good and poor treatment responses and with severe vs. mild adverse reactions continues to be one of the main areas of research and of efforts to transpose these findings into clinical practice.…”

“…Dies gilt insbesondere bei den Krebskrankheiten. Auch die weiteren Punkte dieser hippokratischen Tradition wie „zweitens vorsichtig sein“ und „drittens heilen“ finden ihre Korrelate in den aktuellen Studienergebnissen, den Leitlinien und Therapieempfehlungen 1 , 2 , 3 . Für Karzinome bedeutet dies, dass die Identifikation von Patientinnen mit einer guten und schlechten Prognose, mit einem guten und schlechten Therapieansprechen und schweren vs. leichten Nebenwirkungen nach wie vor eines der Hauptforschungsgebiete und Translationsbestrebungen für die klinische Praxis ist.…”

Update Mammakarzinom 2019 Teil 2 – Implementierung neuer Diagnostika und Therapien bei Patientinnen mit fortgeschrittenem Brustkrebs in der klinischen Praxis

“…Im Zeitalter der Individualisierung von Therapien [1][2][3][4] erreichen aktuell weitere zielgerichtete und immunonkologische Substanzen bei definierten Patientinnengruppen mit fortgeschrittenem Mammakarzinom Zulassungsreife. Der Einsatz von CDK4/6-Inhibitoren bei HER2-negativen und hormonrezeptorpositiven fortgeschrittenen Mammakarzinom-Patientinnen ist Standard.…”

Diagnostic Accuracy of Breast Medical Tactile Examiners (MTEs): A Prospective Pilot Study

“…There has been substantial improvement in the prognosis and treatment of breast cancer [3,4,5,6]. Numerous studies have focused on ways of reducing the morbidity and mortality of breast cancer by improving early cancer detection.…”